Keywords: First-half fiscal 2011/12 financial results, Astellas, Eisai, Santen
Mixed half-year results from Astellas, Eisai and Santen
Article | 02 November 2011
Compared with some of its peers which reported first-half fiscal year 2011/12 (ended September 30) financial results this week, Japanese drug major ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
